文献速递神经肿瘤

每周卡铂单药治疗经治成人恶性胶质瘤的II期研究

Phase II study of weekly carboplatin in pretreated adult malignant gliomas.
PubMed 文献 · J Neurooncol · 2019-07-04

结果显示总体疾病控制率为31.3%,中位无进展生存期2.3个月,总生存期5.5个月;达到临床获益者生存期更长。

要点

  • 每周卡铂单药在经治复发胶质瘤中疾病控制率31.3%
  • 达到临床获益者无进展生存期4.6个月 vs 1.5个月
  • 治疗前使用地塞米松与43.8%患者的临床获益相关

核心结论

  • 每周静脉卡铂单药可能在复发胶质瘤治疗中发挥作用。
  • 治疗前使用皮质激素可能带来生存获益。

主要发现

  • 中位缓解持续时间7.3个月,总体疾病控制率31.3%。
  • 中位无进展生存期2.3个月,总生存期5.5个月。
  • 治疗前使用地塞米松与43.8%患者的临床获益相关。
  • 达到临床获益者无进展生存期4.6个月 vs 1.5个月(p>0.001),总生存期7.9个月 vs 3.2个月(p=0.041)。

关键数值与推荐

  • 入组条件为放疗和化疗后进展或复发的胶质瘤,KPS>60。
  • 所有患者此前接受过基于替莫唑胺和亚硝基脲的化疗。

临床怎么用

  • 对于替莫唑胺和亚硝基脲治疗后进展的成人胶质瘤,每周静脉卡铂单药可考虑作为治疗选项。
  • 治疗前使用地塞米松可能与临床获益相关,需结合患者情况评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with relapse of recurrent glioma have a poor outcome and limited treatment options. The aim of this study is to investigate the clinical benefit and tolerability of weekly intravenous administration of carboplatin-based monotherapy in adult glioma patients who had progressed from previous chemotherapy lines based on temozolomide and nitrosoureas. METHODS: This was a single-arm, phase II study. Eligibility criteria included progressive or recurrent glioma after radiotherapy and chemotherapy-based treatments and Karnofsky performance status (KPS) > 60. RESULTS: Thirty-two patients (median age 43.5 years) were enrolled to receive weekly carboplatin monotherapy in an intravenous method of administration. The median duration of response was 7.3 months with an overall disease control rate of 31.3%. Median progression-free survival was 2.3 months while overall survival was 5.5 months. Pre-treatment with corticosteroids (i.e. dexamethasone) was associated to clinical benefit in 43.8% of patients. Patients achieving clinical benefit exhibited a longer progression-free survival (4.6 vs. 1.5 months; p > 0.001) and overall survival (7.9 vs. 3.2 months; p = 0.041) compared with those not achieving clinical benefit. CONCLUSIONS: Our findings show that single agent, weekly, intravenous administration of carboplatin may have a role in patients with recurrent glioma and suggest that pre-treatment with corticosteroids may confer survival benefit.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Villani V, Pace A, Vidiri A, et al. Phase II study of weekly carboplatin in pretreated adult malignant gliomas. J Neurooncol. 2019. PMID: 31273578. doi:10.1007/s11060-019-03223-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。